Author: PharmaTimes
Unlocking the UK’s virtual drug discovery capability
The UK is well positioned to take advantage of virtual drug discovery services, says Medicines Discovery Catapult’s Graeme Wilkinson
Read More
The Amazon effect
The pharma industry needs to transform the supply chain from a source of regulatory risk to a legitimate business opportunity.
Read More- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
